Ustekinumab’s short-term effect on aortic vascular inflammation points to possible role of IL-12 or IL-23 in cardiovascular disease, but more research is needed.
A Danish study suggests that TNF inhibitors may not increase the risk of developing recurring or new primary cancers in patients with inflammatory diseases.
